Ude, Wikimedia Commons
DNA molecule: A study in Nature Biotechnology has revealed that standard DNA tests miss finding this genetic damage. This has safety implications for future gene therapies using CRISPR/Cas9
Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Reported today (16 July 2018) in the journal Nature Biotechnology, the study also revealed that standard tests for detecting DNA changes miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies.
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells by cutting at specific points and introducing changes at that location. Already extensively used in scientific research, CRISPR/Cas9 has also been seen as a promising way to create potential genome editing treatments for diseases such as HIV, cancer or sickle cell disease. Such therapeutics could inactivate a disease-causing gene, or correct a genetic mutation. However, any potential treatments would have to prove that they were safe.
Previous research had not shown many unforeseen mutations from CRISPR/Cas9 in the DNA at the genome editing target site. To investigate this further the researchers carried out a full systematic study in both mouse and human cells and discovered that CRISPR/Cas9 frequently caused extensive mutations, but at a greater distance from the target site.
The researchers found many of the cells had large genetic rearrangements such as DNA deletions and insertions. These could lead to important genes being switched on or off, which could have major implications for CRISPR/Cas9 use in therapies. In addition, some of these changes were too far away from the target site to be seen with standard genotyping methods.
“This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects.”
Professor Allan Bradley, corresponding author on the study from the Wellcome Sanger Institute
“My initial experiment used CRISPR/Cas9 as a tool to study gene activity, however it became clear that something unexpected was happening. Once we realised the extent of the genetic rearrangements we studied it systematically, looking at different genes and different therapeutically relevant cell lines, and showed that the CRISPR/Cas9 effects held true.”
Michael Kosicki, the first author from the Wellcome Sanger Institute
The work has implications for how CRISPR/Cas9 is used therapeutically and is likely to re-spark researchers’ interest in finding alternatives to the standard CRISPR/Cas9 method for gene editing.
“This study is the first to assess the repertoire of genomic damage arising at a CRISPR/Cas9 cleavage site. While it is not known if genomic sites in other cell lines will be affected in the same way, this study shows that further research and specific testing is needed before CRISPR/Cas9 is used clinically.”
Professor Maria Jasin, an independent researcher from Memorial Slone Kettering Cancer Centre, New York, who was not involved in the study
Learn more: Controversial study raises new doubts over unwanted genetic damage caused by CRISPR
The Latest on: CRISPR/Cas9
[google_news title=”” keyword=”CRISPR/Cas9″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR/Cas9
- FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicineon December 8, 2023 at 6:36 pm
Along with CRISPR/Cas9-based Casgevy—developed by Vertex Pharmaceuticals and CRISPR Therapeutics—the regulator on Friday approved bluebird bio’s Lyfgenia, a second gene therapy for sickle cell disease ...
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussedon December 8, 2023 at 4:06 pm
FDA approves CRISPR-based gene therapy, but CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated stock prices fall. Click for my view of VRTX and CRSP.
- FDA approves first CRISPR therapy—here’s how it works against sickle cellon December 8, 2023 at 3:27 pm
The Food and Drug Administration on Friday approved two gene therapies to treat sickle cell disease, one of the which is the first CRISPR/Cas9-based treatment to win regulatory approval in the US.
- CRISPR-based gene editing therapy approved by the FDA for the first timeon December 8, 2023 at 12:06 pm
The FDA greenlit two new drugs for the treatment of sickle cell disease in patients 12 and older, one of which —Vertex’s drug Casgevy.
- In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell diseaseon December 8, 2023 at 10:15 am
The FDA has approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease.
- Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Diseaseon December 8, 2023 at 9:52 am
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene ...
- What to know about CRISPR gene-editing technologyon December 8, 2023 at 9:25 am
The Food and Drug Administration on Friday approved the first drug that uses this technology to treat an illness, sickle cell disease.
- FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?on December 8, 2023 at 9:22 am
Alongside an historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cel | ...
- ‘Monumental’: FDA approves first CRISPR-based gene-editing drug, marking breakthrough for sickle cell diseaseon December 8, 2023 at 8:47 am
Casgevy was developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, which is headquartered in Zug, Switzerland, but has most of its workforce in Massachusetts.
via Bing News
